Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2005
10/27/2005WO2004068109A3 Autologous or homologous coagulant produced from anticoagulated whole blood
10/27/2005WO2003106643A3 Novel polynucleotides encoding lamprey gnrh-iii
10/27/2005WO2003102016A3 Amyloid peptide inactivating enzyme to treat alzheimer's disease
10/27/2005WO2003076586A3 Nucleic acid-associated proteins
10/27/2005WO2003072595A3 Methods and products based on oligomerization of stress proteins
10/27/2005WO2003023008A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/27/2005US20050241023 Transgenic plants expressing assembled secretory antibodies
10/27/2005US20050241008 Transgenic models of Alzheimer's disease and uses therefor in the treatment of a variety of neurodegenerative diseases
10/27/2005US20050240012 Bispecific molecules for use in inducing antibody dependent effector cell-mediated cytotoxicity
10/27/2005US20050240010 Nucleic acids encoding antagonists of interleukin-15
10/27/2005US20050240009 T-cell epitopes in staphylococcal enterotoxin b
10/27/2005US20050240008 Novel protein, dna thereof and process for producing the same
10/27/2005US20050240006 Cytoplasmic region with more than 107 or less than 104 amino acids, a transmembrance region, and an extracellular region; nucleic acids and antibodies; diagnosing hematopoietic cell malignancy or autoimmune disease
10/27/2005US20050240001 2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; endogenous human growth hormone controller; non-peptidyl in nature, more metabolically stable
10/27/2005US20050239892 Therapeutic avenathramide compounds
10/27/2005US20050239891 Use of citrulline within the framework of intestinal insufficiency
10/27/2005US20050239886 Method of suppressing immune response by reducing intracellular content of glutathione in macrophages and monocytes
10/27/2005US20050239829 Novel piperidine compound
10/27/2005US20050239821 Viral inhibitors
10/27/2005US20050239743 Compositions and methods to inhibit restenosis
10/27/2005US20050239739 Conjugates and compositions for cellular delivery
10/27/2005US20050239735 Enhancement of immune responses
10/27/2005US20050239734 C-class oligonucleotide analogs with enhanced immunostimulatory potency
10/27/2005US20050239729 Incorporating the pro-apoptotic protein BAX and autoantigens adenoviral protein E3-GP19k and Delta BCL-2 into an injectable antidiabetic or hypoglycemic formulation; prevention, diagnosis and monitoring of diabetic patients
10/27/2005US20050239728 Double stranded rna structures and constructs, and methods for generating and using the same
10/27/2005US20050239724 Skin penetration enhancing components
10/27/2005US20050239716 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
10/27/2005US20050239715 Inhibition of allergic contact dermatitis by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester
10/27/2005US20050239714 Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
10/27/2005US20050239713 Novel tubulysin analogues
10/27/2005US20050239711 Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
10/27/2005US20050239710 Peptide that inhibits matrix metalloproteinase-2; incorporated into lotion or wound dressing; can promote the growth of fibroblasts, prevent skin wrinkling, treat scarring, promote smooth healthy skin
10/27/2005US20050239709 Synthetic antimicrobial polypeptides
10/27/2005US20050239708 Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
10/27/2005US20050239707 Combined use of derivatives of GLP-1 analogs and PPAR ligands
10/27/2005US20050239706 Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
10/27/2005US20050239705 Compositions and methods for topical diagnostic and therapeutic transport
10/27/2005US20050239704 Modulation gene expression, drug screening assays, for use as anti-bacterial agents
10/27/2005US20050239703 Antineoplastic urinary protein polypeptide for inhibiting blood vessel formation
10/27/2005US20050239702 Methods of modulating FabH activity
10/27/2005US20050239701 Transient and/or permanent modification of sexual behavior and/or fertility using recombinant chimeric GnRH
10/27/2005US20050239700 Treatment of cancer using antibodies to LRRC15
10/27/2005US20050239699 Remedy for infections
10/27/2005US20050239698 placental growth factor (PLGF) capable of promoting neovascularization in the treatment of diseases and pathological alterations involving the cutaneous or subcutaneous connective tissue, scleroderma and skin ageing due to exposure to chemicals or solar radiation
10/27/2005US20050239697 Methods and compositions for the promotion of hair growth utilizing actin binding peptides
10/27/2005US20050239696 Gmg-3 gmg-4 and gmg-6 polynucleotides and polypeptides and uses thereof
10/27/2005US20050239693 Template-fixed peptidomimetics with antibacterial activity
10/27/2005US20050239692 Aqueous preparation containing oligopeptides and etherified cyclodextrin
10/27/2005US20050239691 Cross-linked glycopeptide - cephalosporin antibiotics
10/27/2005US20050239690 Intermediate for preparing glycopeptide derivatives
10/27/2005US20050239689 Vancomycin analogs and methods thereof
10/27/2005US20050239686 Methods and compositions for optimization of oxygen transport by cell-free systems
10/27/2005US20050239685 Tissue volume reduction
10/27/2005US20050239684 Compounds which inhibit beta-secretase activity and methods of use thereof
10/27/2005US20050239202 Methods and compositions for inhibiting the function of polynucleotide sequences
10/27/2005US20050239171 Method for purifying factor VIII/vWF-complex by means of cation exchange chromatography
10/27/2005US20050239170 Alpha-MSH related compounds and methods of use
10/27/2005US20050239169 Nucleotide sequences coding seladin-1polypeptide for use in treatment and prevention of alzheimer's disease
10/27/2005US20050239168 Detecting moderators of kinase peptide; encoding genes
10/27/2005US20050239167 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide
10/27/2005US20050239164 Glutathione production
10/27/2005US20050239163 Cloning, expression and functional characterization of a mammalian DNA-R gene; polypetide having amino acid sequence with deletion at 1133 1171 amino acids
10/27/2005US20050239141 Modified antibody variable domains
10/27/2005US20050239134 Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
10/27/2005US20050239131 Interactive system for presenting and eliminating substances
10/27/2005US20050239130 Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
10/27/2005US20050239123 Human tumor necrosis receptor TR9
10/27/2005US20050239103 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof
10/27/2005US20050239099 27 human secreted proteins
10/27/2005US20050239094 Compositions and methods for inducing and regulating bone formation
10/27/2005US20050239069 which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells; gene therapy
10/27/2005US20050239064 Methods and compositions based on protein interactions with mastermind
10/27/2005US20050239062 diagnosing Alzheimer's disease by measuring abundance of low-density lipoprotein receptor related protein-1 (LRP-1), abundance of transcripts thereof, or LRP-1 receptor activity and comparing with an age-matched control
10/27/2005US20050238723 Method of producing hydroxyalkyl starch derivatives
10/27/2005US20050238722 Multiblock biodegradable hydrogels for drug delivery and tissue treatment
10/27/2005US20050238720 Stable pharmaceutical composition comprising erythropoietin
10/27/2005US20050238702 Medical composition containing photocrosslinkable chitosan derivative
10/27/2005US20050238694 Satiety inducing composition
10/27/2005US20050238673 compound's solubility in a medium can be enhanced by forming de novo fatty acid or fatty alcohol derived micelles in the presence of the compound; contacting the compound with a fatty acid under conditions in which said fatty acid does not substantially form micelles such as low pH
10/27/2005US20050238667 Botulinum toxin pharmaceutical compositions with enhanced potency with regard to a reference botulinum toxin pharmaceutical composition
10/27/2005US20050238666 Methods of enhancing stem cell engraftment
10/27/2005US20050238664 Botulinum toxin pharmaceutical compositions with multiple stabilizers
10/27/2005US20050238663 Recombinant stabilizer botulinum toxin pharmaceutical compositions
10/27/2005US20050238657 Defective entities and uses therefor
10/27/2005US20050238653 Pharmaceutical compositions containing extracted MHC molecules, for stimulation of the immune system
10/27/2005US20050238651 Treatment of inflammatory bowel disease
10/27/2005US20050238649 Monomethylvaline compounds capable of conjugation to ligands
10/27/2005US20050238648 Composition and method for trating inflammatory disorders
10/27/2005US20050238645 Method and composition for altering a B cell mediated pathology
10/27/2005US20050238644 Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-lL-6 receptor antibody as an active ingredient
10/27/2005US20050238642 Modified bouganin proteins, cytotoxins and methods and uses thereof
10/27/2005US20050238637 Vectors for molecule delivery to CD11b expressing cells
10/27/2005US20050238636 Food supplement formulation
10/27/2005US20050238635 Use of hyrogen peroxide producting enzyme for treatment of otitis media
10/27/2005US20050238634 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
10/27/2005US20050238633 Protease inhibition for prevention or treatment of heart failure
10/27/2005US20050238624 Insulin-like growth factor (IGF-I) plasmid-mediated supplementation for therapeutic applications
10/27/2005US20050238622 Compositions and methods for treating cancer with an oncolytic viral agent
10/27/2005US20050238621 Administering polyoxyethylene glycol modified interferon-alpha
10/27/2005US20050238620 Suppressing fibrosis in a mammal having a fibrosing disease by administering a Serum Amyloid P (SAP) protein; treatment of diseases such as scleroderma, pulmonary fibrosis and asthma
1 ... 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 ... 3163